Second Quarter Revenues of $390.7 Million - - GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 - - Company Reiterates 2025 Financial Expectations ...

Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outper ...